
Aditxt, Inc. — Investor Relations & Filings
Aditxt, Inc. is an innovation company focused on acquiring, developing, and deploying promising health technologies. Its business model involves acquiring disruptive and scalable companies, leveraging its business acceleration platform to drive growth, and monetizing assets through various strategies including mergers, sales, and licenses. The company's portfolio of programs targets significant health challenges. Current programs include Adimune, focused on autoimmunity; Pearsanta, for early cancer detection; and Adivue, for neurological diagnostics. Aditxt also has planned programs and proposed acquisitions in areas such as reproductive health.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-14 | English | |
| S-3 - Aditxt, Inc. (0001726711) (Filer) | 2026-04-11 | English | |
| 8-K/A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-07 | English | |
| DEF 14A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-03 | English | |
| 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-02 | English | |
| 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-03-30 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 34484140 | 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-14 | English | ||
| 34402623 | S-3 - Aditxt, Inc. (0001726711) (Filer) | 2026-04-11 | English | ||
| 33743863 | 8-K/A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-07 | English | ||
| 33302978 | DEF 14A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-03 | English | ||
| 33158825 | 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-02 | English | ||
| 33087919 | 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-03-30 | English | ||
| 33066090 | 424B5 - Aditxt, Inc. (0001726711) (Filer) | 2026-03-27 | English | ||
| 31498298 | 8-K Filing | 2026-02-13 | English | ||
| 31498392 | 8-K Filing | 2026-01-30 | English | ||
| 31498344 | SCHEDULE 13G Filing | 2026-01-30 | English | ||
| 31498281 | 8-K Filing | 2026-01-28 | English | ||
|
2025
4 filings
| |||||
| 13087095 | Director's Dealing 2025 | 2025-12-19 | English | ||
| 13087096 | DEFINITIVE PROXY STATEMENT | 2025-12-16 | English | ||
| 13087097 | PROSPECTUS SUPPLEMENT | 2025-12-12 | English | ||
| 13087099 | REVISED PRELIMINARY PROXY STATEMENT | 2025-12-05 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
PELL BIO-MED TECHNOLOGY CO., LTD.
Develops advanced cell and gene therapies, including CAR-T …
|
6949 | TW | Professional, scientific and te… |
|
PepGen Inc.
Develops oligonucleotide therapeutics for neuromuscular and…
|
PEPG | US | Professional, scientific and te… |
|
PERCHERON THERAPEUTICS LIMITED
Clinical-stage developer of antisense pharmaceuticals for r…
|
PER | AU | Professional, scientific and te… |
|
Perseus Proteomics Inc.
Develops antibody-based therapeutics, diagnostics, and rese…
|
4882 | JP | Professional, scientific and te… |
|
PExA AB
Develops non-invasive technology for respiratory medicine b…
|
PEXA B | SE | Professional, scientific and te… |
|
PharmaResources (Shanghai) Co., Ltd.
Integrated CRO and CDMO for small molecule drug discovery a…
|
301230 | CN | Professional, scientific and te… |
|
Pharmaron Beijing Co., Ltd
Delivers integrated R&D and manufacturing across the entire…
|
3759 | HK | Professional, scientific and te… |
|
Pharmaron Beijing Co., Ltd.
Integrated R&D provider for drug discovery, development, an…
|
300759 | CN | Professional, scientific and te… |
|
Pharos iBio Co., Ltd.
Clinical-stage biotech using AI to develop therapies for ra…
|
388870 | KR | Professional, scientific and te… |
|
Pherecydes Pharma
A clinical-stage biotech company developing phage therapy f…
|
ALPHE | FR | Professional, scientific and te… |
Aditxt, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35447/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35447 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35447 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35447 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35447}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Aditxt, Inc. (id: 35447)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.